Advances in unrelated and alternative donor hematopoietic cell transplantation for nonmalignant disorders
- PMID: 25565572
- PMCID: PMC4403859
- DOI: 10.1097/MOP.0000000000000179
Advances in unrelated and alternative donor hematopoietic cell transplantation for nonmalignant disorders
Abstract
Purpose of review: The role of hematopoietic cell transplantation in non-malignant disorders has increased exponentially with the recognition that multiple diseases can be controlled or cured if engrafted with donor-derived cells. This review provides an overview of advances made in alternative donor transplants for nonmalignant disorders.
Recent findings: Stem cell sources, novel transplant methods, and sophisticated supportive care have simultaneously made giant strides toward improving the safety and efficacy of hematopoietic cell transplantation. This has led to the utilization of marrow, cord, peripheral blood stem cell and haploidentical stem cell sources, and novel reduced toxicity or reduced intensity conditioning regimens to transplant non-malignant disorders such as immune dysfunctions, marrow failure syndromes, metabolic disorders and hemoglobinopathies. Transplant complications such as graft rejection, infections, and graft versus host disease are better combated in this modern era of medicine, achieving better survival with decreased late effects. These aspects of transplant for non-malignant disorders are discussed.
Summary: This review presents the progress made in the realm of hematopoietic cell transplantation for non-malignant disorders. It advocates the consideration of alternative donor transplants in the absence of human leukocyte antigen matched siblings when indicated by disease severity. The ultimate goal is to provide curative transplant options for more patients that can benefit from this intervention, prior to detrimental outcomes.
Similar articles
-
Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.Transpl Immunol. 2005 Aug;14(3-4):207-19. doi: 10.1016/j.trim.2005.03.009. Epub 2005 Apr 26. Transpl Immunol. 2005. PMID: 15982565 Review.
-
Hematopoietic stem cell transplantation from alternative sources in adults with high-risk acute leukemia.Blood Cells Mol Dis. 2004 Nov-Dec;33(3):294-302. doi: 10.1016/j.bcmd.2004.08.021. Blood Cells Mol Dis. 2004. PMID: 15528148
-
Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.Blood Cells Mol Dis. 2008 Jan-Feb;40(1):48-54. doi: 10.1016/j.bcmd.2007.06.019. Epub 2007 Sep 10. Blood Cells Mol Dis. 2008. PMID: 17827036 Review.
-
Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children.Lancet. 2004 Jul 10-16;364(9429):156-62. doi: 10.1016/S0140-6736(04)16628-2. Lancet. 2004. PMID: 15246728
-
Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.Clin Transpl. 2003:275-82. Clin Transpl. 2003. PMID: 15387119 Review.
Cited by
-
Placenta-based therapies for the treatment of epidermolysis bullosa.Cytotherapy. 2015 Jun;17(6):786-795. doi: 10.1016/j.jcyt.2015.03.006. Epub 2015 Mar 18. Cytotherapy. 2015. PMID: 25795271 Free PMC article. Review.
-
Haploidentical Hematopoietic Cell Transplantation Using Post-transplant Cyclophosphamide for Children with Non-malignant Diseases.J Clin Immunol. 2021 Nov;41(8):1754-1761. doi: 10.1007/s10875-021-01113-4. Epub 2021 Aug 6. J Clin Immunol. 2021. PMID: 34355352
-
Decision Making in Adrenoleukodystrophy: When Is a Good Outcome Really a Good Outcome?JAMA Neurol. 2017 Jun 1;74(6):641-642. doi: 10.1001/jamaneurol.2017.0095. JAMA Neurol. 2017. PMID: 28418445 Free PMC article. No abstract available.
-
Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation.Sci Transl Med. 2020 Jan 15;12(526):eaax6249. doi: 10.1126/scitranslmed.aax6249. Sci Transl Med. 2020. PMID: 31941826 Free PMC article.
-
Ovarian tissue cryopreservation in young females through the Oncofertility Consortium's National Physicians Cooperative.Future Oncol. 2018 Feb;14(4):363-378. doi: 10.2217/fon-2017-0410. Epub 2018 Jan 18. Future Oncol. 2018. PMID: 29345507 Free PMC article.
References
-
- Boelens JJ, Aldenhoven M, Purtill D, et al. Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood. 2013;121:3981–7. [good outcomes but better with matched grafts; cord blood transplant outcomes were best.] - PMC - PubMed
-
- Myers KC, Davies S. Hematopoietic stem cell transplantation for bone marrow failure syndromes in children. Biol Blood Marrow Transplant. 2009;15(3):279–92. - PubMed
-
- King A, Shenoy S. Evidence-based focused review of the status of hematopoietic stem cell transplantation as treatment of sickle cell disease and thalassemia. Blood. 2014;123(20):3089–4. - PubMed
-
- EBMT WPIE: EBMT/ESID guideline for HCT for Primary Immunodeficiencies. http://www.ebmt.org/Contents/About-EBMT/Who-We-Are/ScientificCouncil/Doc....
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials